Rex Lear, MD
Psychiatry · Wichita, KSNPI 1962445999
Payments from drug & device makers
Across 656 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$2K
- Otsuka America Pharmaceutical, Inc.$2K
- Alkermes, Inc.$1K
- Neurocrine Biosciences, Inc.$855
- AbbVie$845
- Vanda Pharmaceuticals Inc.$733
- plus $4K from 19 others
What the payments were for
- Food & beverage$11,20299%
- Education$1041%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 76 | $1,778 |
| Otsuka America Pharmaceutical, Inc. | 119 | $1,729 |
| Alkermes, Inc. | 68 | $1,090 |
| Neurocrine Biosciences, Inc. | 66 | $855 |
| AbbVie(2 entities) | 58 | $845 |
| Vanda Pharmaceuticals Inc. | 36 | $733 |
| Lundbeck LLC | 40 | $612 |
| Teva Pharmaceuticals USA, Inc. | 30 | $597 |
| Ironshore Pharmaceuticals Inc. | 7 | $490 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 29 | $475 |
| Sunovion Pharmaceuticals Inc. | 33 | $394 |
| Indivior Inc. | 19 | $274 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $263 |
| E.r. Squibb & Sons, L.L.C. | 11 | $260 |
| Eisai Inc. | 12 | $202 |
| Supernus Pharmaceuticals, Inc. | 9 | $162 |
| Shire North American Group Inc | 8 | $115 |
| Idorsia Pharmaceuticals US Inc | 2 | $115 |
| Corium, LLC | 4 | $84 |
| Merck | 6 | $80 |
| Axsome Therapeutics, Inc. | 4 | $68 |
| Biogen | 2 | $45 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Collegium Pharmaceutical, Inc. | 1 | $14 |
| Tris Pharma Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Jornay PM 20mg capsules (Bottle of 100)$410
- INVEGA SUSTENNA$335
- SPRAVATO$214
- COBENFY$125
- QUVIVIQ$102
How this compares
$11,307 in reported general payments places this provider in the 85th percentile of 259 psychiatry providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 110 | $356,402 |
| IngrezzaValbenazine Tosylate | 17 | $139,342 |
| Abilify MaintenaAripiprazole | 35 | $93,364 |
| Risperdal ConstaRisperidone Microspheres | 26 | $29,932 |
| RexultiBrexpiprazole | 11 | $24,624 |
| TrintellixVortioxetine Hydrobromide | 46 | $22,142 |
| VraylarCariprazine Hcl | 13 | $20,686 |
| LatudaLurasidone Hcl | 11 | $14,673 |
| VyvanseLisdexamfetamine Dimesylate | 33 | $12,932 |
| ConcertaMethylphenidate Hcl | 12 | $10,421 |
| QuviviqDaridorexant Hcl | 13 | $6,945 |
| Seroquel XrQuetiapine Fumarate | 12 | $5,447 |
| Lamotrigine OdtLamotrigine | 13 | $4,702 |
| Paliperidone ErPaliperidone | 25 | $4,161 |
| Lisdexamfetamine Dimesylate | 15 | $3,786 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Risperdal Consta, Concerta | $1,778 | $396,755148 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $855 | $139,34217 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $1,729 | $117,98746 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $263 | $35,07479 claims |
| AbbVieVraylar | $845 | $20,68613 claims |
| Sunovion Pharmaceuticals Inc.Latuda | $394 | $14,67311 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $115 | $6,94513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 259 psychiatry providers in Kansas.
Other psychiatry in Wichita
- Paul MurphyWichita$3.9M
- Matthew ByerlyWichita$792K
- Sheldon PreskornWichita$498K
- Heidi OgdenWichita$55K
- Dwight St ClairWichita$27K
- Ralph BharatiWichita$26K
- Mukhtar ShahWichita$12K
- Lin XuWichita$9K
- Mercedes PeralesWichita$8K
- Jasmine KaurWichita$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.